TVAX Biomedical

11:30 AM - 11:45 AM (EDT), Wednesday, October 23, 2019 ・ 2nd Floor
TVAX Biomedical is a privately held cancer immunotherapy company planning a Ph 2b pivotal study in brain cancer for accelerated approval.
TVAX immunotherapy is specifically an autologous vaccine enhanced adoptive T cell therapy.
We have efficacy in late stage recurrent high grade glioma and metastatic renal cell carcinoma.
We are planning a Ph 2b study in high grade astrocytoma and seeking a strategic and lead investor for this pivotal study.
Company Type:
Company HQ State:
Kansas
Company HQ Country:
United States
Year Founded:
2006
Main Therapeutic Focus:
Lead Product in Development:
TVI-Brain-1
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
President and CEO
TVAX Biomedical